GW Pharmaceuticals Debt/Equity
What is the Debt/Equity of GW Pharmaceuticals?
The Debt/Equity of GW Pharmaceuticals is 1.27
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on NASDAQ compared to GW Pharmaceuticals
Companies with debt/equity similar to GW Pharmaceuticals
- MMTC has Debt/Equity of 1.27
- European Cobalt has Debt/Equity of 1.27
- Boozt AB (publ) has Debt/Equity of 1.27
- Boozt AB (publ) has Debt/Equity of 1.27
- Allreal AG has Debt/Equity of 1.27
- Mazda Motor has Debt/Equity of 1.27
- GW Pharmaceuticals has Debt/Equity of 1.27
- Sky Industries has Debt/Equity of 1.27
- Avidian Gold has Debt/Equity of 1.27
- OM has Debt/Equity of 1.27
- Kontron Ag O.N has Debt/Equity of 1.27
- Itafos has Debt/Equity of 1.27
- Satia Industries has Debt/Equity of 1.27